Небиволол

Quick links

Choose a section

Quick links to important sections

Advertisements

Небиволол

Advertisements
Advertisements

Treatment option: Hypertension, Heart Failure

Advertisements

Overview of Небиволол

Nebivolol Quick Facts

Drug Class Beta-Adrenergic Blocker (Beta-Blocker)
Primary Use Treatment of Hypertension (High Blood Pressure)
Mechanism of Action Selective beta1-receptor blockade and Nitric Oxide-mediated Vasodilation

Nebivolol is a prescription medication used to manage hypertension (high blood pressure) and, in some cases, heart failure. It belongs to a class of drugs called beta-adrenergic receptor blockers, more commonly known as beta-blockers.

How Nebivolol Works

Nebivolol is unique among some beta-blockers due to its dual mechanism of action. Its primary effect is selective blockade of the beta1-adrenergic receptors, which are found predominantly in the heart. Blocking these receptors helps to decrease the heart rate, myocardial contractility, and the rate of electrical conduction, ultimately lowering blood pressure and reducing the heart's workload.

Additionally, nebivolol is considered a third-generation beta-blocker because it also causes vasodilation (widening of blood vessels). This occurs through the stimulation of endothelial nitric oxide synthase, which increases the production of nitric oxide. Nitric oxide helps relax the blood vessels, decreasing systemic vascular resistance and further contributing to blood pressure reduction. By combining the effects of reduced cardiac output and lowered vascular resistance, nebivolol effectively treats high blood pressure. Controlling hypertension is essential for reducing the risk of fatal and nonfatal cardiovascular events, such as stroke and myocardial infarction (heart attack).

Advertisements

What side effects are possible with Небиволол?

Possible side effects and safety information

Nebivolol's official safety profile, documented by regulatory authorities, classifies potential adverse effects based on frequency and the body systems affected. These classifications ensure users are informed about the range of possible outcomes, from commonly observed reactions to rare but serious safety constraints.


Adverse Reaction Classification

Adverse reactions are formally grouped by the System-Organ Class (SOC) categories, which include Nervous System Disorders (e.g., headache, dizziness) and Gastrointestinal Disorders (e.g., constipation, nausea). The frequency of these effects is categorized:

Classification Examples of Documented Effects
Common (1 to 10 in 100 users) Headache, Dizziness, Fatigue, Edema, Paraesthesia
Uncommon (1 to 10 in 1,000 users) Depression, Bradycardia, Vomiting, Impotence

Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights specific, clinically significant safety concerns. Serious adverse reactions include the worsening of heart failure and severe bradycardia. The risk of more severe cardiac events, such as myocardial infarction and ventricular arrhythmias, is noted upon the abrupt cessation of the medicine, particularly in patients with pre-existing coronary artery disease.

Nebivolol is strictly contraindicated in several serious conditions, including severe hepatic impairment, cardiogenic shock, and high-degree Heart Block without a permanent pacemaker. Furthermore, specific safety notes apply to special populations, such as the requirement for a reduced starting dose in patients with severe renal impairment.

Advertisements

Overdose and Emergency Response

The official prescribing information for Nebivolol defines the overdose profile primarily through its expected effects on the cardiovascular system and is managed with supportive care.

Overdose Manifestations and Outcomes Regulatory Action Required
Documented Manifestations Seek Emergency Medical Attention
Overdose may present with serious signs like severe bradycardia (slow heart rate) and pronounced hypotension (low blood pressure), often accompanied by dizziness, extreme fatigue, or vomiting.

| Upon suspected overdose, official regulatory guidance mandates seeking emergency medical attention immediately. | | Severe Complications | Supportive Treatment and Monitoring | | Life-threatening outcomes documented include acute cardiac failure, heart block (second or third degree), severe bronchospasm, and hypoglycemia. In extreme cases, respiratory failure or coma may occur. | Management involves providing general supportive and specific symptomatic treatment. Measures described may include administering atropine for bradycardia or vasopressors for hypotension. Hemodialysis is noted as not expected to enhance the drug's clearance. |

The required immediate action is based on the risk of these severe, potentially life-threatening cardiovascular and respiratory complications. Management is focused on supportive care to address the specific clinical signs present, consistent with regulatory instruction for beta-blocker overdose, including special consideration for low blood sugar in children.

Advertisements

Therapeutic Uses of Небиволол

Небиволол is a medication approved for use in the management of specific cardiovascular health concerns. Its primary therapeutic application is to assist in the control of essential hypertension, commonly referred to as high blood pressure. Maintaining appropriate blood pressure levels is an important component of long-term cardiovascular care.

The medication is also utilized to support the management of certain patients experiencing stable, mild to moderate chronic heart failure. In this setting, Небиволол is used as an adjunctive treatment, supporting overall cardiac function when administered alongside other established therapies. The benefits of this approach are centered on encouraging better heart function and assisting in the sustained control of persistent symptoms associated with these conditions.


Quick Fact: Management of High Blood Pressure

Небиволол is prescribed to help address persistently elevated blood pressure readings.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Небиволол (Nebivolol) — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed: Adults (18 years and older) with essential Hypertension. It is also approved for stable mild to moderate Chronic Heart Failure in certain regulatory regions for patients 70 years and older.

Populations for whom use is contraindicated: Use is absolutely prohibited for patients with severe bradycardia, second or third-degree heart block (without a pacemaker), cardiogenic shock, decompensated cardiac failure, sick sinus syndrome, and severe hepatic impairment (liver failure). It is also contraindicated for those with a history of bronchial asthma.

Age-related eligibility rules: The medicine is not recommended for children and adolescents under 18 years, as its safety and efficacy have not been established in the pediatric population.

Condition-specific eligibility rules:

  • Impaired Organ Function: Use is restricted in patients with severe renal impairment and moderate hepatic impairment.
  • Reproductive Status: Use is not recommended during pregnancy or lactation (breastfeeding), as safety has not been established for the fetus or infant.

Eligibility Classifications

Regulatory documents define these restrictions as Contraindicated (prohibited use), Not Recommended (due to unestablished safety or insufficient data, such as for patients on dialysis), and Conditional Use (requiring caution due to the risk of masking symptoms in conditions like diabetes mellitus or thyrotoxicosis).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nebivolol's interaction profile is structured around two primary regulatory domains: those affecting its concentration in the body and those causing combined physiological effects.

Pharmacokinetic Interactions

Co-administration with potent CYP2D6 enzyme inhibitors (e.g., fluoxetine, quinidine, paroxetine) results in a documented increase in Nebivolol plasma exposure (AUC and Cmax). This pharmacokinetic interaction is due to the inhibition of the enzyme responsible for Nebivolol metabolism. The drug Mavorixafor is a strong CYP2D6 inhibitor and is officially classified as contraindicated for co-administration with Nebivolol.

Pharmacodynamic Interactions

Combining Nebivolol with certain medicinal products can cause additive effects on heart function, which is generally not recommended. This includes non-dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem-type) and Digitalis Glycosides, which may cause an excessive reduction in heart rate (bradycardia). Additionally, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may counteract the antihypertensive effect, reducing the blood pressure-lowering action.

Administration Requirements

To prevent reduced oral bioavailability, administration of Nebivolol should be separated in time from aluminum- or magnesium-containing antacids.

Population-Specific Restrictions

Nebivolol is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) due to significantly decreased metabolism, which heightens the risk of adverse effects. Patients with severe renal impairment also require specific consideration due to decreased clearance.

Advertisements

Mechanism of Action

How Nebivolol Works

Nebivolol's mechanism of action is defined by a dual, synergistic effect on the cardiovascular system. It achieves its physiological effects through two primary, complementary pathways: selective receptor blockade in the heart and the release of an endogenous signaling molecule in the blood vessels.

Selective Blockade of Cardiac Receptors

Nebivolol acts as a highly selective antagonist at the mathbfbeta1 -adrenergic receptor (beta1AR), which is predominantly located in the heart. Blocking these receptors attenuates the stimulating effects of circulating catecholamines. This action produces negative chronotropy (lowering the heart rate) and negative inotropy (decreasing the force of myocardial contraction). This mechanism results in a decrease in cardiac load and myocardial oxygen consumption.

Endothelium-Driven Vascular Widening

The drug promotes the widening of blood vessels through a mechanism involving the endothelium. Nebivolol stimulates the mathbfbeta3 -adrenergic receptor (beta3AR), leading to the activation of Endothelial Nitric Oxide Synthase (eNOS) and subsequent release of Nitric Oxide (NO). NO acts as an endogenous signaling molecule that relaxes the arterial smooth muscle, causing vasodilation and a subsequent reduction in systemic vascular resistance.

Mechanistic Integration

The drug is administered as two different molecular forms (enantiomers) that work together: one is responsible for the cardiac blockade and the other for the NO-mediated vasodilation. This dual, complementary action results in the modulation of both cardiac output and peripheral resistance, influencing overall cardiovascular load. Furthermore, the beta1 blockade also suppresses the release of renin from the kidneys, modulating the initial step of the RAAS pathway, which is involved in systemic fluid and pressure dynamics.

Advertisements

Dosage and Administration Information

How Nebivolol Is Used: Official Administration Guidelines

Administration Scope

Nebivolol is approved for oral administration as a tablet, and therapy is structured around a once daily dosing pattern. The tablet may be taken with or without food but should be administered at the same time each day to maintain consistent blood levels. Scored tablets can be divided to facilitate the use of specific low starting doses required for titration.

Indication Starting Dose Maximum Daily Dose Titration Interval
Hypertension 5 mg once daily 40 mg Every 2 weeks
Chronic Heart Failure (≥ 70 years) 1.25 mg once daily 10 mg Every 1 to 2 weeks

Population and Procedural Rules

The drug’s official use protocol mandates dose adjustments for certain patient populations. For individuals with severe renal or moderate hepatic impairment, the recommended initial dose is 2.5 mg once daily, followed by slow titration. Use is not established for pediatric patients (age < 18 years). Treatment for Chronic Heart Failure requires initial and dose-increase close supervision by a physician.

Discontinuation and Missed Doses: Abrupt cessation of therapy is not permitted. When treatment is discontinued, the dose must be tapered gradually over a period of 1 to 2 weeks. If a dose is missed, the patient should take that day’s dose when remembered, but not double the dose if it is close to the time of the next scheduled intake.


Connection to the overall use protocol: The administration protocol is defined by indication-specific titration schedules and fixed dosing intervals, establishing a standardized, monitored procedure for initiating and adjusting treatment. This structure includes mandatory dose reductions for impaired organ function and formal tapering requirements for stopping therapy, ensuring use remains strictly aligned with established specifications.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Небиволол

This overview describes the types of clinical research conducted on Nebivolol, the outcomes that were observed, and what questions about the medicine are still being explored. It is based on formal regulatory and peer-reviewed scientific information.


Evidence for Use in Essential Hypertension (High Blood Pressure)

Research examining Nebivolol for high blood pressure primarily involves short-term Randomized Controlled Trials (RCTs). The aim of these trials was studied for outcomes related to systemic or functional imbalance, such as measured changes in the blood pressure readings of the enrolled adults over defined time intervals, usually between 6 and 12 weeks. In these research scenarios, the studies monitored the main outcomes: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). The data show patterns related to measured changes in both SBP and DBP in the observed populations. Research has also explored outcomes related to how blood vessels function.

However, the evidence largely describes these short-term changes in blood pressure, which is a surrogate outcome (a measurement that is often used in place of a hard clinical event). The research focusing specifically on Nebivolol has limited information regarding the long-term patterns for major cardiovascular outcomes like avoiding a stroke or a heart attack in the general hypertensive population. Results apply only to the populations studied, which primarily included adults with mild to moderate high blood pressure.


Evidence for Use in Chronic Heart Failure (CHF)

The research on Nebivolol for stable, mild to moderate chronic heart failure was evaluated in a single, large-scale, international, placebo-controlled Randomized Clinical Trial (RCT). This research examined patients with conditions marked by functional limitations and monitored clinical outcomes reflecting daily functioning or activity level. The study specifically focused on older adults who were generally over 70 years of age.

Researchers evaluated a composite endpoint that included all-cause mortality and the frequency of hospital admissions related to the cardiovascular system. The findings described patterns observed in the studies regarding this composite endpoint over the study period. The robust outcome data for heart failure is centered on this single pivotal trial, meaning the results apply only to the populations studied, which were predominantly older adults. Data for certain groups, such as younger individuals with heart failure, remain insufficient within Nebivolol-specific trials.


What Research Gaps and Uncertainties Remain

Research provides insight into short-term changes and group patterns, but it also highlights what is known—and what is still uncertain. Long-term effects are not fully established regarding hard cardiovascular event outcomes for Nebivolol in general hypertension based on Nebivolol-specific trials. Additionally, comparative evidence is lacking for large-scale trials directly comparing Nebivolol to other widely used beta-blockers in the management of both hypertension and heart failure. Subgroup findings are uncertain and data for certain groups remain insufficient. The evidence highlights what is known — and what is still uncertain — as the study results reflect the specific conditions under which they were conducted.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Небиволол (FAQ)


Q: Is Nebivolol considered a 'new generation' beta-blocker?

Official documents describe Nebivolol as having a dual mechanism of action, involving selective beta1 blockade and the widening of blood vessels through nitric oxide. This unique action often leads researchers and medical literature to categorize it as a third-generation beta-blocker. This classification reflects its distinct, complementary effects on the heart and blood vessels.


Q: Are there any specific side effects of Nebivolol that affect men?

The official side effect profile lists impotence (erectile dysfunction) as an uncommon adverse reaction. Uncommon means this effect is reported by 0.1% to 1% of users.


Q: Do people commonly feel tired or fatigued when starting Nebivolol?

Yes, regulatory information lists tiredness and fatigue as common side effects. Common means these effects are reported by 1 to 10 out of every 100 users.


Q: Is weight gain a potential side effect associated with taking Nebivolol?

Official safety information does not list weight gain as a common side effect. However, rapid weight gain is noted as a potential symptom of a more serious condition, such as worsening heart failure. Official guidelines suggest monitoring and discussing any sudden, unexplained weight change with a healthcare provider.


Q: Is it normal to have vivid dreams or sleep issues while using Nebivolol?

Yes, the official side effect profile includes reports of nightmares, sleeplessness, and insomnia (trouble sleeping). These are listed as uncommon or less common psychiatric side effects.


Q: Can Nebivolol cause cold hands and feet?

The official safety profile notes the possibility of symptoms related to Raynaud's phenomenon. These symptoms involve cold, numb, or painful fingers or toes that may change color.


Q: Is it possible to drink alcohol while taking Nebivolol?

Co-administration of Nebivolol and alcohol (ethanol) is classified as a moderate drug interaction. This is because the combination may result in additive effects that can lead to excessive lowering of blood pressure.


Q: Can I take Tylenol (acetaminophen) or ibuprofen while on Nebivolol?

Official regulatory information states that NSAIDs (such as Ibuprofen) may reduce the blood pressure-lowering effect of the drug. Acetaminophen (Tylenol) has no direct interaction reported in the drug label.


Q: Does taking certain supplements affect how Nebivolol works?

Yes, official drug interaction information indicates that certain products like multivitamins with minerals may decrease the effectiveness of Nebivolol. Official documents suggest separating the administration times of these supplements by at least two hours.


Q: Are there any foods that should be avoided when taking Nebivolol?

The official drug label states Nebivolol can be taken with or without food. However, administration should be separated in time from aluminum- or magnesium-containing antacids to prevent a reduction in the amount of drug the body absorbs.


Q: How quickly does Nebivolol start to lower blood pressure after the first dose?

Studies indicate that the peak concentration of the medication in the blood is typically reached 0.5 to 2 hours after administration. However, the full therapeutic effect on reducing overall blood pressure may require several weeks of consistent use.


Q: Is Nebivolol a medication that is intended to be stopped eventually?

Nebivolol is intended to control chronic conditions like high blood pressure and heart failure, but it does not cure them. Official information states treatment should be continued for the duration recommended by a physician. Abrupt cessation is strongly discouraged and requires gradual tapering.


Q: Does Nebivolol have a long half-life compared to other beta-blockers?

The official pharmacokinetic data describes the half-life as approximately 12 hours for the majority of patients. For a small percentage of individuals who metabolize the drug slowly, the half-life may extend up to 19 hours.


Q: Does Nebivolol cause dependence if taken for a long time?

While the drug is not described as causing pharmacological dependence, sudden cessation of therapy is strongly discouraged in official warnings. Stopping abruptly can lead to a withdrawal phenomenon, or discontinuation syndrome, which carries a risk of severe cardiac events.


Q: Is Nebivolol available as a generic drug?

Yes, the active ingredient Nebivolol is available in both its brand name form (Bystolic) and as a lower-cost generic drug.


Q: Are there different brand names for the Nebivolol active ingredient?

Yes, the active ingredient Nebivolol is sold under the Bystolic brand name in certain markets, in addition to being available as a generic tablet.


Q: Is Nebivolol a suitable option for people with diabetes?

Official safety warnings require the drug to be used with caution in people with diabetes. This is because beta-blockers may mask the signs of low blood sugar (hypoglycemia), specifically a rapid heart rate.


Q: Is Nebivolol typically taken once or twice a day according to official guidance?

The official administration protocol is typically structured around a once-daily dosing pattern.


Q: Does the time of day Nebivolol is taken matter?

Official guidance states that the medication should be administered at the same time each day. This helps maintain consistent blood levels, but no specific optimal time (morning versus night) is mandated.


Q: What is the official stance on Nebivolol's effect on cholesterol levels?

Beta-blockers, as a drug class, may alter serum lipid profiles by affecting measurements like VLDL and HDL cholesterol. Official safety information indicates that patients with pre-existing hyperlipidemia (high cholesterol) may require closer monitoring.


Q: Has Nebivolol been studied for use in people with anxiety?

The official FDA-approved indications are only for the treatment of hypertension and heart failure. While it is not approved for anxiety, the side effect profile does list anxiety as an uncommon adverse reaction.


Q: Does official evidence support Nebivolol's use for migraine prevention?

Official regulatory documents state that Nebivolol is FDA-approved only for the treatment of hypertension. Its use for conditions like migraine prevention is considered an off-label use.


Q: Is Nebivolol a blood thinner?

No, Nebivolol is classified as a Beta-Adrenergic Blocking Agent (beta-blocker). Its mechanism involves modulating heart rate and vascular resistance, not preventing blood clots like a blood thinner (anticoagulant).


Q: Does Nebivolol affect the lungs or breathing function?

Official warnings note the potential for respiratory effects. It can cause bronchospasm (uncommon) and is contraindicated (absolutely prohibited) in patients with bronchial asthma.


Q: Can Nebivolol cause depression or mood changes?

Official safety information lists depression as an uncommon side effect, occurring in 0.1% to 1% of users. Other psychological effects like nightmares and anxiety have also been reported.


Q: Does Nebivolol have a specific warning regarding driving or operating machinery?

Yes, the official labeling includes a warning advising caution when driving or operating hazardous machinery until the patient knows how the drug affects their alertness.


Q: Is there an official maximum time limit for using Nebivolol?

There is no official maximum time limit set for the use of Nebivolol. It is intended to be continued for the long-term management of chronic conditions, as determined by a physician.


Q: Can Nebivolol cause an allergic reaction?

Yes, signs of an allergic reaction (such as hives, difficulty breathing, or swelling of the face/throat) are considered serious side effects in official warnings. Signs of a serious allergic reaction require attention from a medical professional.


Q: What does Nebivolol do to blood sugar levels?

Official safety documents indicate that Nebivolol can mask the signs of low blood sugar (hypoglycemia), such as a rapid heart rate. However, some studies also indicate it has little or no direct adverse effect on glucose metabolism.

Advertisements

How should Небиволол be stored and disposed of?

Official Storage and Disposal Instructions for Nebivolol

Nebivolol tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The tablets should be stored in a tightly closed container in a cool, dry place to maintain product stability.

Storage Classification Requirement
Temperature Controlled Room Temperature (20 C-25 C)
Container Tightly closed container, cool, dry place
Safety Keep out of the reach of children

For disposal, contents and containers should be taken to an approved waste disposal plant according to local regulations. It is officially advised not to throw the product into wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Небиволол found in:

A-Z Index: